{"id":32747,"date":"2009-10-26T08:21:10","date_gmt":"2009-10-26T12:21:10","guid":{"rendered":"http:\/\/www.pehub.com\/?p=53719"},"modified":"2009-10-26T08:21:10","modified_gmt":"2009-10-26T12:21:10","slug":"becton-dickinson-buying-handylab","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/32747","title":{"rendered":"Becton Dickinson Buying HandyLab"},"content":{"rendered":"

\"\"<\/a>Becton, Dickinson and Co.<\/strong> (NYSE: BDX) has agreed to acquire HandyLab Inc.<\/strong>, an Ann Arbor, Mich.-based maker of molecular diagnostic assays and automation platforms. No financial terms were disclosed. HandyLab had raised nearly $44 million in VC funding, from firms like EDF Ventures, Ardesta, Arboretum Ventures, Pfizer Strategic Investments, Wolverine Venture Fund, Dow Ventures and Lurie Investments.<\/p>\n

PRESS RELEASE<\/span><\/strong>
\nBD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it signed a definitive agreement to acquire HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms. The acquisition is subject to regulatory approvals and is expected to close during the first quarter of fiscal year 2010. The financial terms of the agreement were not disclosed.<\/p>\n

Consistent with BD\u2019s stated acquisition strategy, and building upon a previously announced development and distribution agreement between BD and HandyLab earlier in 2009, the acquisition would further extend BD\u2019s commitment to the novel HandyLab instrumentation technology to support BD\u2019s molecular diagnostics strategy.<\/p>\n

\u201cHandyLab has developed and commercialized a flexible automated platform for performing molecular diagnostics which is an ideal complement to our molecular diagnostics offerings,\u201d said Vincent A. Forlenza, BD President. \u201cWe believe this new platform enables both our healthcare-associated infections offering and future expansion into other molecular opportunities.\u201d<\/p>\n

BD plans to place its BD GeneOhm\u2122 molecular assays for Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile and Vancomycin-resistant Enterococcus (VRE) onto the HandyLab platform and market them as the new BD MAX\u2122 system. The flexibility of this novel platform will allow further expansion of the BD molecular diagnostic menu. BD senior management will address this announcement during the Company\u2019s fiscal fourth quarter earnings call on November 4, 2009, which will be broadcast live on BD’s website, www.bd.com\/investors, at 10:00 a.m. (ET).<\/p>\n

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com<\/p>\n

ShareThis<\/a><\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

\n<\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Becton, Dickinson and Co. (NYSE: BDX) has agreed to acquire HandyLab Inc., an Ann Arbor, Mich.-based maker of molecular diagnostic assays and automation platforms. No financial terms were disclosed. HandyLab had raised nearly $44 million in VC funding, from firms like EDF Ventures, Ardesta, Arboretum Ventures, Pfizer Strategic Investments, Wolverine Venture Fund, Dow Ventures and […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-32747","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/32747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=32747"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/32747\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=32747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=32747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=32747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}